Research update on the anticancer effects of buparlisib (Review)
- Authors:
- Jinshan Xing
- Jun Yang
- Yingjiang Gu
- Jingyan Yi
-
Affiliations: Department of Neurosurgery, The Affiliated Traditional Chinese Medicine Hospital of Southwest Medical University, Luzhou, Sichuan 646000, P.R. China, Department of Medical Cell Biology and Genetics, School of Basic Medical Sciences, Southwest Medical University, Luzhou, Sichuan 646000, P.R. China - Published online on: February 9, 2021 https://doi.org/10.3892/ol.2021.12527
- Article Number: 266
This article is mentioned in:
Abstract
Fruman DA, Meyers RE and Cantley LC: Phosphoinositide kinases. Annu Rev Biochem. 67:481–507. 1998. View Article : Google Scholar : PubMed/NCBI | |
Katso R, Okkenhaug K, Ahmadi K, White S, Timms J and Waterfield MD: Cellular function of phosphoinositide 3-kinases: Implications for development, homeostasis, and cancer. Annu Rev Cell Dev Biol. 17:615–675. 2001. View Article : Google Scholar : PubMed/NCBI | |
Nobukuni T, Kozma SC and Thomas G: hvps34, an ancient player, enters a growing game: mTOR Complex1/S6K1 signaling. Curr Opin Cell Biol. 19:135–141. 2007. View Article : Google Scholar : PubMed/NCBI | |
Dornan GL and Burke JE: Molecular mechanisms of human disease mediated by oncogenic and primary immunodeficiency mutations in Class IA phosphoinositide 3-kinases. Front Immunol. 9:5752018. View Article : Google Scholar : PubMed/NCBI | |
Bader AG, Kang S, Zhao L and Vogt PK: Oncogenic PI3K deregulates transcription and translation. Nat Rev Cancer. 5:921–929. 2005. View Article : Google Scholar : PubMed/NCBI | |
Suire S, Coadwell J, Ferguson GJ, Davidson K, Hawkins P and Stephens L: p84, a new Gbetagamma-activated regulatory subunit of the type IB phosphoinositide 3-kinase p110gamma. Curr Biol. 15:566–570. 2005. View Article : Google Scholar : PubMed/NCBI | |
Voigt P, Dorner MB and Schaefer M: Characterization of p87PIKAP, a novel regulatory subunit of phosphoinositide 3-kinase gamma that is highly expressed in heart and interacts with PDE3B. J Biol Chem. 281:9977–9986. 2006. View Article : Google Scholar : PubMed/NCBI | |
Gulluni F, De Santis MC, Margaria JP, Martini M and Hirsch E: Class II PI3K functions in cell biology and disease. Trends Cell Biol. 29:339–359. 2019. View Article : Google Scholar : PubMed/NCBI | |
Rommel C: Taking PI3Kδ and PI3Kγ one step ahead: Dual active PI3Kδ/γ inhibitors for the treatment of immune-mediated inflammatory diseases. Curr Top Microbiol Immunol. 346:279–299. 2010.PubMed/NCBI | |
Mayer IA and Arteaga CL: PIK3CA activating mutations: A discordant role in early versus advanced hormone-dependent estrogen receptor-positive breast cancer? J Clin Oncol. 32:2932–2934. 2014. View Article : Google Scholar : PubMed/NCBI | |
Martínez-Sáez O, Chic N, Pascual T, Adamo B, Vidal M, González-Farré B, Sanfeliu E, Schettini F, Conte B, Brasó-Maristany F, et al: Frequency and spectrum of PIK3CA somatic mutations in breast cancer. Breast Cancer Res. 22:452020. View Article : Google Scholar : PubMed/NCBI | |
Stephens LR, Jackson TR and Hawkins PT: Agonist-stimulated synthesis of phosphatidylinositol(3,4,5)-trisphosphate: A new intracellular signalling system? Biochim Biophys Acta. 1179:27–75. 1993. View Article : Google Scholar : PubMed/NCBI | |
Vanhaesebroeck B, Leevers SJ, Ahmadi K, Timms J, Katso R, Driscoll PC, Woscholski R, Parker PJ and Waterfield MD: Synthesis and function of 3-phosphorylated inositol lipids. Annu Rev Biochem. 70:535–602. 2001. View Article : Google Scholar : PubMed/NCBI | |
Foster FM, Traer CJ, Abraham SM and Fry MJ: The phosphoinositide (PI) 3-kinase family. J Cell Sci. 116:3037–3040. 2003. View Article : Google Scholar : PubMed/NCBI | |
Wymann MP, Zvelebil M and Laffargue M: Phosphoinositide 3-kinase signalling-which way to target? Trends Pharmacol Sci. 24:366–376. 2003. View Article : Google Scholar : PubMed/NCBI | |
Oudit GY, Sun H, Kerfant BG, Crackower MA, Penninger JM and Backx PH: The role of phosphoinositide-3 kinase and PTEN in cardiovascular physiology and disease. J Mol Cell Cardiol. 37:449–471. 2004. View Article : Google Scholar : PubMed/NCBI | |
Maehama T, Taylor GS and Dixon JE: PTEN and myotubularin: Novel phosphoinositide phosphatases. Annu Rev Biochem. 70:247–279. 2001. View Article : Google Scholar : PubMed/NCBI | |
DiNitto JP, Cronin TC and Lambright DG: Membrane recognition and targeting by lipid-binding domains. Sci STKE. 2003:re162003.PubMed/NCBI | |
Miralem T, Lerner-Marmarosh N, Gibbs PE, Jenkins JL, Heimiller C and Maines MD: Interaction of human biliverdin reductase with Akt/protein kinase B and phosphatidylinositol-dependent kinase 1 regulates glycogen synthase kinase 3 activity: A novel mechanism of Akt activation. FASEB J. 30:2926–2944. 2016. View Article : Google Scholar : PubMed/NCBI | |
Kang SA, O'Neill DJ, Machl AW, Lumpkin CJ, Galda SN, Sengupta S, Mahoney SJ, Howell JJ, Molz L, Hahm S, et al: Discovery of small-molecule selective mTORC1 inhibitors via direct inhibition of glucose transporters. Cell Chem Biol. 26:1203–1213.e13. 2019. View Article : Google Scholar : PubMed/NCBI | |
Hua H, Kong Q, Zhang H, Wang J, Luo T and Jiang Y: Targeting mTOR for cancer therapy. J Hematol Oncol. 12:712019. View Article : Google Scholar : PubMed/NCBI | |
Jacinto E, Loewith R, Schmidt A, Lin S, Rüegg MA, Hall A and Hall MN: Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive. Nat Cell Biol. 6:1122–1128. 2004. View Article : Google Scholar : PubMed/NCBI | |
Jacinto E, Facchinetti V, Liu D, Soto N, Wei S, Jung SY, Huang Q, Qin J and Su B: SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates Akt phosphorylation and substrate specificity. Cell. 127:125–137. 2006. View Article : Google Scholar : PubMed/NCBI | |
Engelman JA, Luo J and Cantley LC: The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet. 7:606–619. 2006. View Article : Google Scholar : PubMed/NCBI | |
Darici S, Alkhaldi H, Horne G, Jørgensen HG, Marmiroli S and Huang X: Targeting PI3K/Akt/mTOR in AML: Rationale and clinical evidence. J Clin Med. 9:29342020. View Article : Google Scholar | |
Raza W, Luqman S and Meena A: Prospects of tangeretin as a modulator of cancer targets/pathways. Pharmacol Res. 161:1052022020. View Article : Google Scholar : PubMed/NCBI | |
Wen W, Marcinkowski E, Luyimbazi D, Luu T, Xing Q, Yan J, Wang Y, Wu J, Guo Y, Tully D, et al: Eribulin synergistically increases anti-tumor activity of an mTOR inhibitor by inhibiting pAKT/pS6K/pS6 in triple negative breast cancer. Cells. 8:10102019. View Article : Google Scholar | |
Meng C, Xia Q, Wu H, Huang H, Liu H, Li Y, Zhang F and Song W: Photobiomodulation with 630-nm LED radiation inhibits the proliferation of human synoviocyte MH7A cells possibly via TRPV4/PI3K/AKT/mTOR signaling pathway. Lasers Med Sci. 35:1927–1936. 2020. View Article : Google Scholar : PubMed/NCBI | |
Verret B, Cortes J, Bachelot T, Andre F and Arnedos M: Efficacy of PI3K inhibitors in advanced breast cancer. Ann Oncol. 30 (Suppl):10:x12-x20. 2019. View Article : Google Scholar | |
Liu N, Rowley BR, Bull CO, Schneider C, Haegebarth A, Schatz CA, Fracasso PR, Wilkie DP, Hentemann M, Wilhelm SM, et al: BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models. Mol Cancer Ther. 12:2319–2330. 2013. View Article : Google Scholar : PubMed/NCBI | |
O'Brien C, Wallin JJ, Sampath D, GuhaThakurta D, Savage H, Punnoose EA, Guan J, Berry L, Prior WW, Amler LC, et al: Predictive biomarkers of sensitivity to the phosphatidylinositol 3′ kinase inhibitor GDC-0941 in breast cancer preclinical models. Clin Cancer Res. 16:3670–3683. 2010. View Article : Google Scholar : PubMed/NCBI | |
Sarker D, Ang JE, Baird R, Kristeleit R, Shah K, Moreno V, Clarke PA, Raynaud FI, Levy G, Ware JA, et al: First-in-human phase I study of pictilisib (GDC-0941), a potent pan-class I phosphatidylinositol-3-kinase (PI3K) inhibitor, in patients with advanced solid tumors. Clin Cancer Res. 21:77–86. 2015. View Article : Google Scholar : PubMed/NCBI | |
Raynaud FI, Eccles SA, Patel S, Alix S, Box G, Chuckowree I, Folkes A, Gowan S, De Haven Brandon A, Di Stefano F, et al: Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941. Mol Cancer Ther. 8:1725–1738. 2009. View Article : Google Scholar : PubMed/NCBI | |
Ragon BK, Kantarjian H, Jabbour E, Ravandi F, Cortes J, Borthakur G, DeBose L, Zeng Z, Schneider H, Pemmaraju N, et al: Buparlisib, a PI3K inhibitor, demonstrates acceptable tolerability and preliminary activity in a phase I trial of patients with advanced leukemias. Am J Hematol. 92:7–11. 2017. View Article : Google Scholar : PubMed/NCBI | |
Heudel PE, Fabbro M, Roemer-Becuwe C, Kaminsky MC, Arnaud A, Joly F, Roche-Forestier S, Meunier J, Foa C, You B, et al: Phase II study of the PI3K inhibitor BKM120 in patients with advanced or recurrent endometrial carcinoma: A stratified type I-type II study from the GINECO group. Br J Cancer. 116:303–309. 2017. View Article : Google Scholar : PubMed/NCBI | |
Matulonis UA, Wulf GM, Barry WT, Birrer M, Westin SN, Farooq S, Bell-McGuinn KM, Obermayer E, Whalen C, Spagnoletti T, et al: Phase I dose escalation study of the PI3kinase pathway inhibitor BKM120 and the oral poly (ADP ribose) polymerase (PARP) inhibitor olaparib for the treatment of high-grade serous ovarian and breast cancer. Ann Oncol. 28:512–518. 2017. View Article : Google Scholar : PubMed/NCBI | |
Bedard PL, Tabernero J, Janku F, Wainberg ZA, Paz-Ares L, Vansteenkiste J, Van Cutsem E, Pérez-García J, Stathis A, Britten CD, et al: A phase Ib dose-escalation study of the oral pan-PI3K inhibitor buparlisib (BKM120) in combination with the oral MEK1/2 inhibitor trametinib (GSK1120212) in patients with selected advanced solid tumors. Clin Cancer Res. 21:730–738. 2015. View Article : Google Scholar : PubMed/NCBI | |
Maira SM, Pecchi S, Huang A, Burger M, Knapp M, Sterker D, Schnell C, Guthy D, Nagel T, Wiesmann M, et al: Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor. Mol Cancer Ther. 11:317–328. 2012. View Article : Google Scholar : PubMed/NCBI | |
Tamura K, Kodaira M, Shimizu C, Yonemori K, Yunokawa M, Shimomura A, Kobayashi T, Nakano K, Tomomatsu J, Ito Y, et al: Phase I study of taselisib in Japanese patients with advanced solid tumors or hormone receptor-positive advanced breast cancer. Cancer Sci. 109:1592–1601. 2018. View Article : Google Scholar : PubMed/NCBI | |
Juric D, Krop I, Ramanathan RK, Wilson TR, Ware JA, Sanabria Bohorquez SM, Savage HM, Sampath D, Salphati L, Lin RS, et al: Phase I dose-escalation study of taselisib, an oral PI3K inhibitor, in patients with advanced solid tumors. Cancer Discov. 7:704–715. 2017. View Article : Google Scholar : PubMed/NCBI | |
Edelman G, Rodon J, Lager J, Castell C, Jiang J, Van Allen EM, Wagle N, Lindeman NI, Sholl LM and Shapiro GI: Phase I trial of a tablet formulation of pilaralisib, a Pan-class I PI3K inhibitor, in patients with advanced solid tumors. Oncologist. 23:401–e38. 2018. View Article : Google Scholar : PubMed/NCBI | |
Wheler J, Mutch D, Lager J, Castell C, Liu L, Jiang J and Traynor AM: Phase I dose-escalation study of pilaralisib (SAR245408, XL147) in combination with paclitaxel and carboplatin in patients with solid tumors. Oncologist. 22:377–e37. 2017. View Article : Google Scholar : PubMed/NCBI | |
Abramson V, Supko J, Ballinger T, Cleary JM, Hilton JF, Tolaney SM, Chau NG, Cho DC, Pearlberg J, Lager J, et al: Phase Ib study of safety and pharmacokinetics of the PI3K inhibitor SAR245408 with the HER3-neutralizing human antibody SAR256212 in patients with solid tumors. Clin Cancer Res. 23:3520–3528. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Liu J, Qiu Y, Jin M, Chen X, Fan G, Wang R and Kong D: ZSTK474, a specific class I phosphatidylinositol 3-kinase inhibitor, induces G1 arrest and autophagy in human breast cancer MCF-7 cells. Oncotarget. 7:19897–19909. 2016. View Article : Google Scholar : PubMed/NCBI | |
Lockhart AC, Olszanski AJ, Allgren RL, Yaguchi S, Cohen SJ, Hilton JF, Wang-Gillam A and Shapiro GI: Abstract B271: A first-in-human phase I study of ZSTK474, an oral pan-PI3K inhibitor, in patients with advanced solid malignancies. Mol Cancer Ther. 12:B271. 2013. | |
Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, et al: A phase II study of PX-866 in patients with recurrent or metastatic castration-resistant prostate cancer: Canadian cancer trials Group Study IND205. Clin Genitourin Cancer. 17:201–208.e201. 2019. View Article : Google Scholar : PubMed/NCBI | |
Pitz MW, Eisenhauer EA, MacNeil MV, Thiessen B, Easaw JC, Macdonald DR, Eisenstat DD, Kakumanu AS, Salim M, Chalchal H, et al: Phase II study of PX-866 in recurrent glioblastoma. Neuro Oncol. 17:1270–1274. 2015.PubMed/NCBI | |
Zhang N, Caenepeel S, Wang L, Norman M, Kendall R, Burgess T, Radinsky R, Hughes P and Freeman DJ: Abstract 2797: AMG 511, a potent and selective class I PI3K inhibitor, demonstrates anti-tumor activity in multiple xenograft models. Cancer Res. 72:2797. 2012. | |
Fiascarelli A, Merlino G, Capano S, Paoli A, Bressan A, Bigion M, Scaltrit M, Arribas J, Bernadó Morales C, Pellacani A, et al: 1938P Characterization of the mechanism of action and efficacy of MEN1611 (PA799), a novel PI3K inhibitor, in breast cancer preclinical models. Ann Oncol. 302019.doi: 10.1093/annonc/mdz268.065. | |
Speranza MC, Nowicki MO, Behera P, Cho CF, Chiocca EA and Lawler SE: BKM-120 (Buparlisib): A phosphatidyl-inositol-3 kinase inhibitor with anti-invasive properties in glioblastoma. Sci Rep. 6:201892016. View Article : Google Scholar : PubMed/NCBI | |
Robert M, Frenel J, Bourbouloux E, Berton Rigaud D, Patsouris A, Augereau P, Gourmelon C and Campone M: Efficacy of buparlisib in treating breast cancer. Expert Opin Pharmacother. 18:2007–2016. 2017. View Article : Google Scholar : PubMed/NCBI | |
Matulonis U, Wulf GM, Birrer MJ, Westin SN, Quy P, Bell-McGuinn K, Lasonde B, Whalen C, Aghajanian C, Solit DB, et al: Phase I study of oral BKM120 and oral olaparib for high-grade serous ovarian cancer (HGSC) or triple-negative breast cancer (TNBC). J Clin Oncol. 32:25102014. View Article : Google Scholar | |
Matulonis UA, Wulf G, Barry W, Birrer M, Birrer M, Westin S, Spagnoletti T, Bell-McGuinn K, Obermayer E, Whalen C, et al: Abstract CT324: Phase I of oral BKM120 or BYL719 and olaparib for high-grade serous ovarian cancer or triple-negative breast cancer: Final results of the BKM120 plus olaparib cohort. Cancer Res. 75:CT3242015. | |
Wang J, Li H, He G, Chu Z, Peng K, Ge Y, Zhu Q and Xu Y: Discovery of novel dual poly(ADP-ribose)polymerase and phosphoinositide 3-kinase inhibitors as a promising strategy for cancer therapy. J Med Chem. 63:122–139. 2020. View Article : Google Scholar : PubMed/NCBI | |
Owonikoko TK, Harvey RD, Carthon B, Chen Z, Lewis C, Collins H, Zhang C, Lawson DH, Alese OB, Bilen MA, et al: A Phase I study of safety, pharmacokinetics, and pharmacodynamics of concurrent everolimus and buparlisib treatment in advanced solid tumors. Clin Cancer Res. 26:2497–2505. 2020. View Article : Google Scholar : PubMed/NCBI | |
Bousmail D, Amrein L, Fakhoury JJ, Fakih HH, Hsu JCC, Panasci L and Sleiman HF: Precision spherical nucleic acids for delivery of anticancer drugs. Chem Sci. 8:6218–6229. 2017. View Article : Google Scholar : PubMed/NCBI | |
de Gooijer M, Zhang P, Buil LCM, Çitirikkaya CH, Thota N, Beijnen JH and van Tellingen O: Buparlisib is a brain penetrable pan-PI3K inhibitor. Sci Rep. 8:107842018. View Article : Google Scholar : PubMed/NCBI | |
Saura C, Bendell J, Jerusalem G, Su S, Ru Q, De Buck S, Mills D, Ruquet S, Bosch A, Urruticoechea A, et al: Phase Ib study of buparlisib plus trastuzumab in patients with HER2-positive advanced or metastatic breast cancer that has progressed on Trastuzumab-based therapy. Clin Cancer Res. 20:1935–1945. 2014. View Article : Google Scholar : PubMed/NCBI | |
Bavelloni A, Focaccia E, Piazzi M, Orsini A, Ramazzotti G, Cocco L, Blalock W and Faenza I: Therapeutic potential of nvp-bkm120 in human osteosarcomas cells. J Cell Physiol. 234:10907–10917. 2019. View Article : Google Scholar : PubMed/NCBI | |
Müller A, Gillissen B, Richter A, Richter A, Chumduri C, Daniel PT and Scholz CW: Pan-class I PI3-kinase inhibitor BKM120 induces MEK1/2-dependent mitotic catastrophe in non-Hodgkin lymphoma leading to apoptosis or polyploidy determined by Bax/Bak and p53. Cell Death Dis. 9:3842018. View Article : Google Scholar : PubMed/NCBI | |
Zhao P, Hall J, Durston M, Voydanoff A, VanSickle E, Kelly S, Nagulapally AB, Bond J and Saulnier Sholler G: BKM120 induces apoptosis and inhibits tumor growth in medulloblastoma. PLoS One. 12:e01799482017. View Article : Google Scholar : PubMed/NCBI | |
Lonetti A, Antunes IL, Chiarini F, Orsini E, Buontempo F, Ricci F, Tazzari PL, Pagliaro P, Melchionda F, Pession A, et al: Activity of the pan-class I phosphoinositide 3-kinase inhibitor NVP-BKM120 in T-cell acute lymphoblastic leukemia. Leukemia. 28:1196–1206. 2014. View Article : Google Scholar : PubMed/NCBI | |
Sun B, Jensen NR, Chung D, Yang M, LaRue AC, Cheung HW and Wang Q: Synergistic effects of SHP2 and PI3K pathway inhibitors in GAB2-overexpressing ovarian cancer. Am J Cancer Res. 9:145–159. 2019.PubMed/NCBI | |
Yu F, Zhao J, Hu Y, Zhou Y, Guo R, Bai J, Zhang S, Zhang H and Zhang J: The combination of NVP-BKM120 with trastuzumab or RAD001 synergistically inhibits the growth of breast cancer stem cells in vivo. Oncol Rep. 36:356–364. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chen IC, Hsiao LP, Huang IW, Yu HC, Yeh LC, Lin CH, Wei-Wu Chen T, Cheng AL and Lu YS: Phosphatidylinositol-3 kinase inhibitors, buparlisib and alpelisib, sensitize estrogen receptor-positive breast cancer cells to tamoxifen. Sci Rep. 7:98422017. View Article : Google Scholar : PubMed/NCBI | |
Alipour F, Riyahi N, Safaroghli-Azar A, Sari S, Zandi Z and Bashash D: Inhibition of PI3K pathway using BKM120 intensified the chemo-sensitivity of breast cancer cells to arsenic trioxide (ATO). Int J Biochem Cell Biol. 116:1056152019. View Article : Google Scholar : PubMed/NCBI | |
Solberg NT, Waaler J, Lund K, Mygland L, Olsen PA and Krauss S: TANKYRASE inhibition enhances the antiproliferative effect of PI3K and EGFR inhibition, mutually affecting β-CATENIN and AKT signaling in colorectal cancer. Mol Cancer Res. 16:543–553. 2018. View Article : Google Scholar : PubMed/NCBI | |
Yao W, Yue P, Zhang G, Owonikoko TK, Khuri FR and Sun SY: Enhancing therapeutic efficacy of the MEK inhibitor, MEK162, by blocking autophagy or inhibiting PI3K/Akt signaling in human lung cancer cells. Cancer Lett. 364:70–78. 2015. View Article : Google Scholar : PubMed/NCBI | |
Blanco B, Herrero-Sanchez C, Rodriguez-Serrano C, Sanchez-Barba M and Del Canizo MC: Comparative effect of two pan-class I PI3K inhibitors used as anticancer drugs on human T cell function. Int Immunopharmacol. 28:675–685. 2015. View Article : Google Scholar : PubMed/NCBI | |
Schimmer AD, Hedley DW, Penn LZ and Minden MD: Receptor- and mitochondrial-mediated apoptosis in acute leukemia: A translational view. Blood. 98:3541–3553. 2001. View Article : Google Scholar : PubMed/NCBI | |
Pereira JK, Machado-Neto JA, Lopes MR, Morini BC, Traina F, Costa FF, Saad ST and Favaro P: Molecular effects of the phosphatidylinositol-3-kinase inhibitor NVP-BKM120 on T and B-cell acute lymphoblastic leukaemia. Eur J Cancer. 51:2076–2085. 2015. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Li Q, Huang P, Tong D, Wu H and Zhang F: EGFR-mediated signaling pathway influences the sensitivity of oral squamous cell carcinoma to JQ1. J Cell Biochem. 119:8368–8377. 2018. View Article : Google Scholar : PubMed/NCBI | |
Bian X, Gao J, Luo F, Rui C, Zheng T, Wang D, Wang Y, Roberts TM, Liu P, Zhao JJ and Cheng H: PTEN deficiency sensitizes endometrioid endometrial cancer to compound PARP-PI3K inhibition but not PARP inhibition as monotherapy. Oncogene. 37:341–351. 2018. View Article : Google Scholar : PubMed/NCBI | |
Philip CA, Laskov I, Beauchamp MC, Marques M, Amin O, Bitharas J, Kessous R, Kogan L, Baloch T, Gotlieb WH and Yasmeen A: Inhibition of PI3K-AKT-mTOR pathway sensitizes endometrial cancer cell lines to PARP inhibitors. BMC Cancer. 17:6382017. View Article : Google Scholar : PubMed/NCBI | |
Bashash D, Safaroghli-Azar A, Delshad M, Bayati S, Nooshinfar E and Ghaffari SH: Inhibitor of pan class-I PI3K induces differentially apoptotic pathways in acute leukemia cells: Shedding new light on NVP-BKM120 mechanism of action. Int J Biochem Cell Biol. 79:308–317. 2016. View Article : Google Scholar : PubMed/NCBI | |
Preyat N and Leo O: Sirtuin deacylases: A molecular link between metabolism and immunity. J Leukoc Biol. 93:669–680. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bashash D, Delshad M, Riyahi N, Safaroghli-Azar A, Pourbagheri-Sigaroodi A and Momeny M: Inhibition of PI3K signaling pathway enhances the chemosensitivity of APL cells to ATO: Proposing novel therapeutic potential for BKM120. Eur J Pharmacol. 841:10–18. 2018. View Article : Google Scholar : PubMed/NCBI | |
Safaroghli-Azar A, Bashash D, Kazemi A, Pourbagheri-Sigaroodi A and Momeny M: Anticancer effect of pan-PI3K inhibitor on multiple myeloma cells: Shedding new light on the mechanisms involved in BKM120 resistance. Eur J Pharmacol. 842:89–98. 2019. View Article : Google Scholar : PubMed/NCBI | |
Zhang Y, Nie L, Xu K, Fu Y, Zhong J, Gu K and Zhang L: SIRT6, a novel direct transcriptional target of FoxO3a, mediates colon cancer therapy. Theranostics. 9:2380–2394. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wang S, Niu X, Bao X, Wang Q and Zhang J, Lu S, Wang Y, Xu L, Wang M and Zhang J: The PI3K inhibitor buparlisib suppresses osteoclast formation and tumour cell growth in bone metastasis of lung cancer, as evidenced by multimodality molecular imaging. Oncol Rep. 41:2636–2646. 2019.PubMed/NCBI | |
Trautmann M, Cyra M, Isfort I, Jeiler B, Krüger A, Grünewald I, Steinestel K, Altvater B, Rossig C, Hafner S, et al: Phosphatidylinositol-3-kinase (PI3K)/Akt signaling is functionally essential in myxoid liposarcoma. Mol Cancer Ther. 18:834–844. 2019. View Article : Google Scholar : PubMed/NCBI | |
Jin L, Jin MH, Nam AR, Park JE, Bang JH, Oh DY and Bang YJ: Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. Cancer Lett. 411:162–170. 2017. View Article : Google Scholar : PubMed/NCBI | |
Parrales A and Iwakuma T: Targeting oncogenic mutant p53 for cancer therapy. Front Oncol. 5:2882015. View Article : Google Scholar : PubMed/NCBI | |
Li Z, Xu X, Li Y, Zou K, Zhang Z, Xu X, Liao Y, Zhao X, Jiang W, Yu W, et al: Synergistic antitumor effect of BKM120 with Prima-1-met via inhibiting PI3K/AKT/mTOR and CPSF4/hTERT signaling and reactivating mutant P53. Cell Physiol Biochem. 45:1772–1786. 2018. View Article : Google Scholar : PubMed/NCBI | |
Aasen SN, Parajuli H, Hoang T, Feng Z, Stokke K, Wang J, Roy K, Bjerkvig R, Knappskog S and Thorsen F: Effective treatment of metastatic melanoma by combining MAPK and PI3K signaling pathway inhibitors. Int J Mol Sci. 20:42352019. View Article : Google Scholar | |
Li M, Liang RF, Wang X, Mao Q and Liu YH: BKM120 sensitizes C6 glioma cells to temozolomide via suppression of the PI3K/Akt/NF-kappaB/MGMT signaling pathway. Oncol Lett. 14:6597–6603. 2017.PubMed/NCBI | |
De Martino D, Yilmaz E, Orlacchio A, Ranieri M, Zhao K and Di Cristofano A: PI3K blockage synergizes with PLK1 inhibition preventing endoreduplication and enhancing apoptosis in anaplastic thyroid cancer. Cancer Lett. 439:56–65. 2018. View Article : Google Scholar : PubMed/NCBI | |
Sai J, Owens P, Novitskiy SV, Hawkins OE, Vilgelm AE, Yang J, Sobolik T, Lavender N, Johnson AC, McClain C, et al: PI3K inhibition reduces mammary tumor growth and facilitates antitumor immunity and Anti-PD1 responses. Clin Cancer Res. 23:3371–3384. 2017. View Article : Google Scholar : PubMed/NCBI | |
Anisuzzaman AS, Haque A, Wang D, Rahman MA, Zhang C, Chen Z, Chen ZG, Shin DM and Amin AR: In vitro and in vivo synergistic antitumor activity of the combination of BKM120 and erlotinib in head and neck cancer: Mechanism of apoptosis and resistance. Mol Cancer Ther. 16:729–738. 2017. View Article : Google Scholar : PubMed/NCBI | |
Yun MR, Choi HM, Kang HN, Lee Y, Joo HS, Kim DH, Kim HR, Hong MH, Yoon SO and Cho BC: ERK-dependent IL-6 autocrine signaling mediates adaptive resistance to pan-PI3K inhibitor BKM120 in head and neck squamous cell carcinoma. Oncogene. 37:377–388. 2017. View Article : Google Scholar : PubMed/NCBI | |
Liu X, Wu H, Huang P and Zhang F: JQ1 and PI3K inhibition synergistically reduce salivary adenoid cystic carcinoma malignancy by targeting the c-Myc and EGFR signaling pathways. J Oral Pathol Med. 48:43–51. 2019. View Article : Google Scholar : PubMed/NCBI | |
Sakakibara K, Tsujioka T, Kida JI, Kurozumi N, Nakahara T, Suemori SI, Kitanaka A, Arao Y and Tohyama K: Binimetinib, a novel MEK1/2 inhibitor, exerts anti-leukemic effects under inactive status of PI3Kinase/Akt pathway. Int J Hematol. 110:213–227. 2019. View Article : Google Scholar : PubMed/NCBI | |
Wang D, Li C, Zhang Y, Wang M, Jiang N, Xiang L, Li T, Roberts TM, Zhao JJ, Cheng H and Liu P: Combined inhibition of PI3K and PARP is effective in the treatment of ovarian cancer cells with wild-type PIK3CA genes. Gynecol Oncol. 142:548–556. 2016. View Article : Google Scholar : PubMed/NCBI | |
Yang L, Yang G, Ding Y, Huang Y, Liu S, Zhou L, Wei W, Wang J and Hu G: Combined treatment with PI3K inhibitor BKM120 and PARP inhibitor olaparib is effective in inhibiting the gastric cancer cells with ARID1A deficiency. Oncol Rep. 40:479–487. 2018.PubMed/NCBI | |
Qiu Y, Pu T, Guo P, Wei B, Zhang Z, Zhang H, Zhong X, Zheng H, Chen L, Bu H and Ye F: ALDH+/CD44+ cells in breast cancer are associated with worse prognosis and poor clinical outcome. Exp Mol Pathol. 100:145–150. 2016. View Article : Google Scholar : PubMed/NCBI | |
Wu L, Meng F, Dong L, Block CJ, Mitchell AV, Wu J, Jang H, Chen W, Polin L, Yang Q, et al: Disulfiram and BKM120 in combination with chemotherapy impede tumor progression and delay tumor recurrence in tumor initiating cell-rich TNBC. Sci Rep. 9:2362019. View Article : Google Scholar : PubMed/NCBI | |
Zhao H, Yang Q, Hu Y and Zhang J: Antitumor effects and mechanisms of olaparib in combination with carboplatin and BKM120 on human triple-negative breast cancer cells. Oncol Rep. 40:3223–3234. 2018.PubMed/NCBI | |
Yan G, Ru Y, Wu K, Yan F, Wang Q, Wang J, Pan T, Zhang M, Han H, Li X and Zou L: GOLM1 promotes prostate cancer progression through activating PI3K-AKT-mTOR signaling. Prostate. 78:166–177. 2017. View Article : Google Scholar : PubMed/NCBI | |
Varambally S, Laxman B, Mehra R, Cao Q, Dhanasekaran SM, Tomlins SA, Granger J, Vellaichamy A, Sreekumar A, Yu J, et al: Golgi protein GOLM1 is a tissue and urine biomarker of prostate cancer. Neoplasia. 10:1285–1294. 2008. View Article : Google Scholar : PubMed/NCBI | |
Foster KA, Jane EP, Premkumar DR, Morales A and Pollack IF: NVP-BKM120 potentiates apoptosis in tumor necrosis factor-related apoptosis-inducing ligand-resistant glioma cell lines via upregulation of Noxa and death receptor 5. Int J Oncol. 47:506–516. 2015. View Article : Google Scholar : PubMed/NCBI | |
Radovich M, Solzak JP, Hancock BA, Conces ML, Atale R, Porter RF, Zhu J, Glasscock J, Kesler KA, Badve SS, et al: A large microRNA cluster on chromosome 19 is a transcriptional hallmark of WHO type A and AB thymomas. Br J Cancer. 114:477–484. 2016. View Article : Google Scholar : PubMed/NCBI | |
Bukum N, Novotna E, Morell A, Hofman J and Wsol V: Buparlisib is a novel inhibitor of daunorubicin reduction mediated by aldo-keto reductase 1C3. Chem Biol Interact. 302:101–107. 2019. View Article : Google Scholar : PubMed/NCBI | |
Hamid AR, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FC, Sedelaar JP and Schalken JA: Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med. 18:1449–1455. 2013. View Article : Google Scholar : PubMed/NCBI | |
Jiang ZB, Huang J, Xie C, Li X, Liu L, He J, Pan H, Huang L, Fan XX, Yao XJ, et al: Combined use of PI3K and MEK inhibitors synergistically inhibits lung cancer with EGFR and KRAS mutations. Oncol Rep. 36:365–375. 2016. View Article : Google Scholar : PubMed/NCBI |